

# CARMIGNAC PORTFOLIO MERGER ARBITRAGE PLUS: LETTER FROM THE FUND MANAGERS

23/01/2024 | FABIENNE CRETIN-FUMERON, STÉPHANE DIEUDONNÉ

Dear Investors,


*During the last quarter of the year, our Carmignac Merger Arbitrage (I share class EUR Acc) achieved a performance of 1%, while Carmignac Merger Arbitrage Plus (I share class EUR Acc) rose 1.1%.*

**In the last quarter, M&A activity showed a real rebound compared with the previous quarter.** Indeed, 86 M&A deals announced in the US, Europe and Asia during Q4 2023 were eligible for our portfolio, which was up 32% on the previous quarter. As usual, the US remains the largest market with 48% of the total, with Europe and Asia sharing the remainder with 26% and 27% each. The average deal size is \$6 billion in the US, compared with around \$2 billion in Europe and Asia. **When we look at M&A activity by value, the upturn is even more notable, with a total of \$340 billion worth of deals announced in the last quarter, almost double the figure for the previous quarter.**

The final quarter is also a good time to take stock of the M&A year that has just ended. At the start of the year, many thought that rising interest rates in the US and Europe would bring M&A activity to a halt. While it is true that there has been a decline in value this year, a detailed analysis reveals a more complex reality. In fact, **M&A activity has decreased overall in value in 2023 compared with 2022: deals announced during this year represented a total of \$991bn, an annual decline of 20%.** There are several points to bear in mind when analysing this figure.

Firstly, **this fall is actually smaller than one might have feared at the start of the year, given the scale and speed of the rise in interest rates.**


Secondly, **the level of activity achieved this year is in line with what was seen on average before 2018, when rates were significantly lower.** The geographical disparity is also interesting to note: while the US is down by 20%, Europe is down more sharply by 44%, while Asia is up by 41%.



Source: Carmignac, Bloomberg as of 31/12/2023.

Finally, **if we look not at value but at volume, i.e. the number of transactions, the fall in M&A activity is much more modest. With 294 new deals announced for 2023, the fall is only 6% on 2022.**

This is an important point to emphasise because, for us as arbitrageurs, it is the number of transactions, rather than the size of the deals themselves, that enables us to deploy capital in our funds while maintaining good diversification.




Source: Carmignac, Bloomberg as of 31/12/2023.

The sectoral breakdown of M&A activity is also interesting to analyse, as it reflects a real change from what we have seen in the recent past, and probably foreshadows a new trend for the future.

**We are witnessing the return of the "old economy".** While Healthcare and Technology remain two important sectors, accounting for 20% and 11% respectively of total announced deals in the US, Energy has become the leading sector with 26% and Industrials/Commodities the third with 14%. In Asia, the trend is even more pronounced, with the Industrial/Raw Materials and Utilities sectors together accounting for almost 70% of the total. **The drivers behind this trend are powerful and structural: sector growth driven by the energy transition, a solid balance sheet for strategic players, and significant synergies and economies of scale in the event of mergers.**

**The final highlight of the year is the gradual return of "mega deals" in the US, i.e. deals in excess of \$10bn, which had disappeared from the landscape somewhat during 2022.** This type of deal had become the Federal Trade Commission's (FTC) favourite target, particularly in key sectors such as technology (Activision, VMWare, Black Knight) and healthcare (Seagen). But the fact that the FTC failed to block some of these emblematic deals, such as Activision and Seagen, has probably given companies renewed confidence to embark on major external growth projects.



*Source: Carmignac, Bloomberg as of 31/12/2023.*

With the fall in the US 10-year yield and the prospect of the end of the cycle of key rate hikes, the equity and bond markets rebounded strongly in the last quarter of 2023, with the S&P 500 and US Investment Grade up 11.7% and 10.0% respectively. Looking at the Merger Arbitrage strategy, our Carmignac Merger Arbitrage (I share class EUR Acc) and Carmignac Merger Arbitrage Plus (I share class EUR Acc) funds posted a more modest increase of 1% and 1.1% respectively, but which remains entirely satisfactory in terms of management objectives. Several factors explain this performance.

Firstly, **the pressure from the anti-trust authorities, which we had seen at the start of the year, particularly in the USA, tended to normalise throughout 2023.** Two major deals, Pfizer's \$41bn takeover of Seagen and Cisco's \$28bn acquisition of Splunk, were approved by the FTC during the fourth quarter.

**We also benefited from two improved offers. The first was the result of the stock market battle to buy the management company Sculptor Capital between Rithm Capital and a group of investors led by Boaz Weinstein.** Rithm Capital's initial offer was eventually increased by almost 14%. **The second improved offer concerns the mining company Azure Minerals.** Sociedad Quimica y Minera de Chile, a leading Chilean lithium miner, initially launched a standalone offer at AU\$3.50, which was subsequently increased by almost 6% with the support of Australian company Hancock Prospecting.

Finally, **a large number of transactions, 88 in total in the US, came to an end during the quarter. The convergence of discounts on these deals was a good performance driver at the end of the year.**

On the other hand, several factors had a negative impact on the fund's performance during the quarter. **While the FTC approved a number of major deals, it also launched in-depth investigations into two other transactions, Tapestry's acquisition of Capri Holdings in the luxury handbag sector and Campbell Soup's acquisition of Sovo in the food sector.** Although partly anticipated by the market, this bad news led to a widening of the two discounts, creating greater volatility.

The other **negative factor of the month was the high volatility of discounts in the oil sector, particularly the one on the Hess/Chevron deal.** Tensions between Venezuela and Guyana escalated in December over the territorial dispute centred on the Essequibo region. After holding a referendum on Venezuelan sovereignty over the Essequibo, Venezuela launched a defensive military manoeuvre on the border between the two countries. As Hess holds the vast majority of its assets in Guyana, the discount on the deal initially fell sharply before tightening at the end of the month following a meeting between the Venezuelan and Guyanese heads of state mediated by Brazil. We note that the merger agreement between Hess and Chevron is extremely strong and that the escalation of tensions alone cannot be a sufficient reason to withdraw from this operation. Chevron has also reaffirmed its interest in acquiring Hess.


Finally, **despite significant improvements, Brookfield and EIG Global Energy's bid for Australian power producer Origin Energy failed as a result of shareholder opposition led by the Australian Super pension fund.** As we had correctly estimated the Origin Energy share price in the event of the deal failing, the impact on performance was limited.

Another way of breaking down the fund's performance is to look at the status of the deal at the end of the period. A bid can be either:

- In progress: the deal has not yet been finalised because all the conditions precedent have not yet been lifted;
- Closed: the transaction has been finalised in accordance with the initial terms;
- Improved: the buyer has increased its price or a third party has come in with a higher offer;
- Abandoned: the deal failed.


Using this methodology, we obtain the following performance attribution table for Carmignac Portfolio Merger Arbitrage Plus:

Merger Arb gross performance attribution in Q4 2023



Source: Carmignac, Bloomberg as of 31/12/2023.

Merger Arb gross performance attribution in Q4 2023



Source: Carmignac, Bloomberg as of 31/12/2023.

The table for Carmignac Portfolio Merger Arbitrage is as follows:

The main driver of performance was the completion of a large number of transactions in the portfolio. Given the increased volatility on certain discounts such as Sovo, Capri and Hess, the 'Pending' category contributed little to performance during the quarter. It should also be noted that the failure of the Origin Energy deal was more than offset by improved offers, notably the one for Sculptor.

This year-end is also an opportunity to take stock, since the funds were created in April 2023, of the two other key management parameters: volatility and correlation with the main asset classes.

**In a year that was ultimately turbulent for all markets, our Merger Arbitrage strategy delivered on its promise of controlled volatility and low correlation. Carmignac Portfolio Merger Arbitrage has a volatility of 0.7% and a correlation to equities of 0.24 and High Yield credit of 0.12.**

**Carmignac Portfolio Merger Arbitrage Plus has a volatility of 2.1% and a correlation to equities of 0.26 and to High Yield credit of 0.14.**

For the year ahead, we are confident that the good momentum seen in Q4 2023 will continue. Indeed, a historical study of M&A activity shows that, while there is a degree of cyclical, downturns in activity tend on average to be short-lived. **For 2024, the drivers of the recovery are already there:**

- The **end of the rate hike cycle is approaching**, which should give business leaders a degree of visibility;
- **Return of mega deals** in most economic sectors;
- **Sectoral shift in M&A activity towards the "old economy"**, driven in particular by the energy transition;
- **A greater proportion of strategic players than financial players**, who are more penalised by high interest rates;
- In some sectors, such as technology and healthcare, **external growth is structurally an integral part of development models.**

*The Merger Arbitrage Team*

SFDR - Fund Classification\*\* :

Article **8**



Recommended minimum investment horizon



## MAIN RISKS OF THE FUND

**EQUITY:** The Fund may be affected by stock price variations, the scale of which is dependent on external factors, stock trading volumes or market capitalization. **ARBITRAGE:** Arbitrage seeks to benefit from such price differences (e.g. in markets, sectors, securities, currencies). If arbitrage performs unfavorably, an investment may lose its value and generate a loss for the Sub-Fund. **RISK ASSOCIATED WITH THE LONG/SHORT STRATEGY:** This risk is linked to long and/or short positions designed to adjust net market exposure. The Fund may suffer high losses if its long and short positions undergo simultaneous unfavourable development in opposite directions. **LIQUIDITY:** Temporary market distortions may have an impact on the pricing conditions under which the Fund might be caused to liquidate, initiate or modify its positions.

**The Fund presents a risk of loss of capital.**

\* \*\*Risk Scale from the KID (Key Information Document). Risk 1 does not mean a risk-free investment. This indicator may change over time.

\*\*The Sustainable Finance Disclosure Regulation (SFDR) 2019/2088 is a European regulation that requires asset managers to classify their funds as either 'Article 8' funds, which promote environmental and social characteristics, 'Article 9' funds, which make sustainable investments with measurable objectives, or 'Article 6' funds, which do not necessarily have a sustainability objective. For more information please refer to <https://eur-lex.europa.eu/eli/reg/2019/2088/oj>.

## FEES

**Entry costs :** We do not charge an entry fee.

**Exit costs :** We do not charge an exit fee for this product.

**Management fees and other administrative or operating costs :** 1,11% of the value of your investment per year. This estimate is based on actual costs over the past year.

**Performance fees :** 20,00% max. of the outperformance if the performance is positive and the net asset value exceeds the high-water mark. The actual amount will vary depending on how well your investment performs. The aggregated cost estimation above includes the average over the last 5 years, or since the product creation if it is less than 5 years.

**Transaction Cost :** 0,84% of the value of your investment per year. This is an estimate of the costs incurred when we buy and sell the investments underlying the product. The actual amount varies depending on the quantity we buy and sell.

ANNUALISED PERFORMANCE (ISIN: LU2585801330)

Calendar Year Performance (as %)	2023
Carmignac Portfolio Merger Arbitrage Plus	+3.2 %

Annualised Performance	1 Year	3 Years	Since launch
Carmignac Portfolio Merger Arbitrage Plus	+3.9 %	- %	+3.5 %

Source: Carmignac at 30 Apr 2024.

Past performance is not necessarily indicative of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor).

**Marketing communication. Please refer to the KID/KIID, prospectus of the fund before making any final investment decisions. This document is intended for professional clients.**

This material may not be reproduced, in whole or in part, without prior authorisation from the Management Company. This material does not constitute a subscription offer, nor does it constitute investment advice. This material is not intended to provide, and should not be relied on for, accounting, legal or tax advice. This material has been provided to you for informational purposes only and may not be relied upon by you in evaluating the merits of investing in any securities or interests referred to herein or for any other purposes. The information contained in this material may be partial information and may be modified without prior notice. They are expressed as of the date of writing and are derived from proprietary and non-proprietary sources deemed by Carmignac to be reliable, are not necessarily all-inclusive and are not guaranteed as to accuracy. As such, no warranty of accuracy or reliability is given and no responsibility arising in any other way for errors and omissions (including responsibility to any person by reason of negligence) is accepted by Carmignac, its officers, employees or agents.

Past performance is not necessarily indicative of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor). The return may increase or decrease as a result of currency fluctuations, for the shares which are not currency-hedged.

Reference to certain securities and financial instruments is for illustrative purposes to highlight stocks that are or have been included in the portfolios of funds in the Carmignac range. This is not intended to promote direct investment in those instruments, nor does it constitute investment advice. The Management Company is not subject to prohibition on trading in these instruments prior to issuing any communication. The portfolios of Carmignac funds may change without previous notice. The reference to a ranking or prize, is no guarantee of the future results of the UCIS or the manager.

Morningstar Rating™ : © Morningstar, Inc. All Rights Reserved. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

Access to the Funds may be subject to restrictions regarding certain persons or countries. This material is not directed to any person in any jurisdiction where (by reason of that person's nationality, residence or otherwise) the material or availability of this material is prohibited. Persons in respect of whom such prohibitions apply must not access this material. Taxation depends on the situation of the individual. The Funds are not registered for retail distribution in Asia, in Japan, in North America, nor are they registered in South America. Carmignac Funds are registered in Singapore as restricted foreign scheme (for professional clients only). The Funds have not been registered under the US Securities Act of 1933. The Funds may not be offered or sold, directly or indirectly, for the benefit or on behalf of a «U.S. person», according to the definition of the US Regulation S and FATCA.

The risks, fees and ongoing charges are described in the KID (Key Information Document). The KID must be made available to the subscriber prior to subscription. The subscriber must read the KID. Investors may lose some or all their capital, as the capital in the funds are not guaranteed. The Funds present a risk of loss of capital.

The Funds' prospectus, KIDs, NAVs and annual reports are available at [www.carmignac.com](http://www.carmignac.com), or upon request to the Management Company. Carmignac Portfolio refers to the sub-funds of Carmignac Portfolio SICAV, an investment company under Luxembourg law, conforming to the UCITS Directive. The French investment funds (fonds communs de placement or FCP) are common funds in contractual form conforming to the UCITS or AIFM Directive under French law.

- **In France, Luxembourg, Sweden:** The risks, fees and ongoing charges are described in the KID (Key Information Document). The KID must be made available to the subscriber prior to subscription. The subscriber must read the KID. Investors may lose some or all their capital, as the capital in the funds are not guaranteed. The Funds present a risk of loss of capital. The Funds' prospectus, KIDs, NAV and annual reports are available at [www.carmignac.com](http://www.carmignac.com), or upon request to the Management Company.
- **In the United Kingdom:** the Funds' respective prospectuses, KIIDs and annual reports are available at [www.carmignac.co.uk](http://www.carmignac.co.uk), or upon request to the Management Company, or for the French Funds, at the offices of the Facilities Agent at BNP PARIBAS SECURITIES SERVICES, operating through its branch in London: 55 Moorgate, London EC2R. This document was prepared by Carmignac Gestion, Carmignac Gestion Luxembourg or Carmignac UK Ltd. FP Carmignac ICVC (the "Company") is an Investment Company with variable capital incorporated in England and Wales under registered number 839620 and is authorised by the FCA with effect from 4 April 2019 and launched on 15 May 2019. FundRock Partners Limited is the Authorised Corporate Director (the "ACD") of the Company and is authorised and regulated by the FCA. Registered Office: Hamilton Centre, Rodney Way, Chelmsford, Essex, CM1 3BY, UK; Registered in England and Wales with number 4162989. Carmignac Gestion Luxembourg SA has been appointed as the Investment Manager and distributor in respect of the Company. Carmignac UK Ltd (Registered in England and Wales with number 14162894) has been appointed as a sub-Investment Manager of the Company and is authorised and regulated by the Financial Conduct Authority with FRN:984288.
- **In Switzerland:** the prospectus, KIDs and annual report are available at [www.carmignac.ch](http://www.carmignac.ch), or through our representative in Switzerland, CACEIS (Switzerland), S.A., Route de Signy 35, CH-1260 Nyon. The paying agent is CACEIS Bank, Montrouge, Nyon Branch / Switzerland, Route de Signy 35, 1260 Nyon.

The Management Company can cease promotion in your country anytime.

Investors have access to a summary of their rights in English on the following links: [UK](#) ; [Switzerland](#) ; [France](#) ; [Luxembourg](#) ; [Sweden](#).